Syndax Files Registration Statement for Proposed Initial Public Offering

WALTHAM, Mass., March 27, 2014 /PRNewswire/ --Syndax Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Syndax. The number of shares to be offered and the price range for the offering have not yet been determined.

Deutsche Bank Securities and Jefferies are acting as joint book-running managers for the offering. JMP Securities and Wedbush PacGrow Life Sciences are acting as co-managers.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836 or by telephone at: [phone], or by email at: [e-mail]; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, telephone: [phone], e-mail: [e-mail].

About Syndax Pharmaceuticals

Syndax is developing entinostat for the treatment of patients with therapy-resistant cancers. Entinostat is designed to prolong the effectiveness of current cancer treatments through an epigenetic mechanism and has been designated a Breakthrough Therapy by the FDA when used in combination with exemestane in estrogen receptor positive metastatic breast cancer. Syndax holds worldwide rights to entinostat, an oral, selective HDAC inhibitor that is being evaluated in combination with exemestane in a pivotal Phase 3 clinical study for the treatment of hormone receptor positive metastatic breast cancer.

Corporate Contact:
Bob Goodenow
Chief Business Officer
Syndax Pharmaceuticals
[phone]
[e-mail]

Investor Contact:
Robert Flamm, Ph.D.
Russo Partners
[phone]
[e-mail]

Media Contacts:
David Schull or Matt Middleman, M.D.
Russo Partners
[phone]
[phone]
[e-mail]
[e-mail]

SOURCE Syndax Pharmaceuticals, Inc.